HMG-CoA reductase inhibitor (statin)
Rosuvastatin
Rosuvastatin after one dose: 50% at ~19 h, 25% at 38 h, 12.5% at 57 h.
Drawn from the half-life in the app's model, ~19 h. The model's figures
- Compound
- Rosuvastatin
- Symbol
- ROS
- Family
- Post-cycle and ancillaries
- Parts
- 14
- References
- 8
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Rosuvastatin is an HMG-CoA reductase inhibitor (statin) sold in the United States as Crestor by AstraZeneca.1 The US label gives 2003 as the initial approval year.1 The label lists one use to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for these events.1 It also lists use as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia, and in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia.1 The label also lists slowing the progression of atherosclerosis in adults, and, as an adjunct to diet, treatment of adults with primary dysbetalipoproteinemia and with hypertriglyceridemia.1 The app grades the evidence for rosuvastatin as strong; the pivotal outcome trial described below, JUPITER, was funded by AstraZeneca.4,5 The app lists rosuvastatin as an oral compound with a typical dose of 5 to 40 mg per day.
How it works
Sources in this part
The label describes rosuvastatin as an inhibitor of HMG-CoA reductase, "the rate-limiting enzyme" that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.1 On the label, inhibition of the enzyme "accelerates the expression of LDL-receptors", followed by uptake of LDL-C from blood to the liver and a decrease in plasma LDL-C and total cholesterol.1 The label adds that the maximum LDL-C reduction "is usually achieved by 4 weeks and is maintained after that".1 The label names rosuvastatin as a substrate of CYP2C9 and of transporters such as OATP1B1 and BCRP.1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~19 h
- Bioavailability
- 20%
- Typical dose
- 5–40 mg/day
- Route
- Oral
- Time to peak
- ~4 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~19 h | Approximately 19 hours on the Crestor label; geometric mean 10.9 hours (geometric CV 38%, range 1.7 to 45.5) after a single dose in 247 healthy volunteers1,2 |
| Bioavailability | 20% | Absolute bioavailability of approximately 20% on the label1 |
| Time to peak | ~4 h | Peak plasma concentrations 3 to 5 hours after oral dosing on the label; median 5 hours (range 0.5 to 8) in the 247 healthy volunteers1,2 |
| Volume of distribution | Not listed in the app | Mean steady-state volume of distribution of approximately 134 liters on the label1 |
| Metabolism | Roughly 10% metabolised, mainly via CYP2C9 | Approximately 10% of a radiolabeled dose recovered as metabolite; clearance not dependent on CYP3A4 metabolism to a clinically significant extent1 |
The app's half-life figure of 19 hours matches the label, which states that "the elimination half-life of rosuvastatin is approximately 19 hours".1 A pharmacogenomic study by Lehtisalo and colleagues reported a lower geometric mean of 10.9 hours across 247 healthy volunteers, with individual values from 1.7 to 45.5 hours.2 The sources used do not explain the gap between the two figures. The label states that the AUC "does not differ following evening or morning drug administration" and that food "did not affect the AUC".1
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once daily1.
An illustration from a pharmacokinetic model using a half-life of 19 hours. It is not a measured level or a suggested dose.
Specific populations on the label
The label reports an approximate 2-fold elevation in median exposure (AUC and Cmax) in Asian subjects compared with a White control group, in pharmacokinetic studies that included one conducted in the US.1 Mild to moderate renal impairment "had no influence on plasma concentrations", while concentrations rose about 3-fold in severe renal impairment (CLcr under 30 mL/min/1.73 m2) not receiving hemodialysis.1
Deeper analysis: SLCO1B1, ABCG2 and SLCO2B1 genotypes (Lehtisalo and colleagues, 2023)
Lehtisalo and colleagues at the University of Helsinki and Helsinki University Hospital published the study in the British Journal of Clinical Pharmacology in 2023.2 The design was a genome-wide association study and candidate gene analysis of single-dose rosuvastatin pharmacokinetics in a prospective study (n = 159) and a cohort of previously published studies (n = 88).2 The dose was 40 mg in the prospective study and 10 to 20 mg in the earlier studies, with values adjusted to a 40 mg dose.2 The group with the poorest OATP1B1 function (a phenotype derived from SLCO1B1 genotype) had an area under the curve 2.1-fold higher than the normal-function group (90% confidence interval 1.6 to 2.8).2 The highly increased function group had a 44% lower area under the curve (90% confidence interval 16% to 62%).2 The ABCG2 c.421A/A genotype associated with a 2.2-fold increase (1.5 to 3.0).2 The authors conclude that "poor SLCO1B1 or ABCG2 function genotypes may increase the risk of rosuvastatin-induced myotoxicity".2 The label is more cautious: higher concentrations were reported in "very small groups of patients (n=3 to 5)" with two reduced-function OATP1B1 alleles, and "the impact of this polymorphism on efficacy and/or safety of CRESTOR has not been clearly established".1 The authors' stated limitations include that the study was "carried out in healthy participants", and that effects of some variants "could have remained undetected due to their low frequencies in the Finnish population".2 Funding came from the European Research Council, the Sigrid Jusélius Foundation, the Orion Research Foundation and the Finnish Medical Foundation, and the authors declare no conflicts of interest.2
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Ridker and colleagues, JUPITER, New England Journal of Medicine 20083 | Randomised, double-blind, placebo-controlled phase 3 trial; AstraZeneca was lead sponsor and the trial was stopped early4 | 17,802 apparently healthy men and women with LDL cholesterol under 130 mg/dL and hsCRP 2.0 mg/L or higher3 | Rosuvastatin 20 mg daily or placebo; median follow-up 1.9 years (maximum 5.0)3 | Primary end point 0.77 against 1.36 per 100 person-years (hazard ratio 0.56, 95% CI 0.46 to 0.69); all-cause death hazard ratio 0.80 (0.67 to 0.97); no significant increase in myopathy or cancer, but a higher incidence of physician-reported diabetes on rosuvastatin3 |
| Ridker and colleagues, JUPITER diabetes analysis, Lancet 20125 | Prespecified secondary outcomes of the same trial, analysed by diabetes risk factors chosen post hoc; AstraZeneca-funded5 | 17,603 participants without prior cardiovascular disease or diabetes (11,508 with at least one major diabetes risk factor, 6,095 with none)5 | Rosuvastatin 20 mg or placebo; up to 5 years5 | With risk factors: primary end point hazard ratio 0.61 (0.47 to 0.79), diabetes hazard ratio 1.28 (1.07 to 1.54). Without: 0.48 (0.33 to 0.68) and 0.99 (0.45 to 2.21). All participants: diabetes 270 against 216 reports (hazard ratio 1.25, 1.05 to 1.49)5 |
| Peña and colleagues, JUPITER fracture analysis, JAMA Internal Medicine 20156 | Prespecified secondary end point of JUPITER; double-blind, placebo-controlled; JUPITER supported by AstraZeneca6 | 17,802 men older than 50 years and women older than 60 years with hs-CRP of at least 2 mg/L6 | Rosuvastatin 20 mg daily or placebo; median 1.9 years6 | 221 confirmed fractures on rosuvastatin and 210 on placebo (adjusted hazard ratio 1.06, 95% CI 0.88 to 1.28; P = .53)6 |
| Jones and colleagues, STELLAR, American Journal of Cardiology 20037 | Open-label, randomised, parallel-group, multicentre comparison with three other statins7 | 2,431 adults with hypercholesterolemia7 | Rosuvastatin 10, 20, 40 or 80 mg, or atorvastatin, simvastatin or pravastatin at 10 to 80 mg (pravastatin to 40 mg); 6 weeks7 | Across doses, rosuvastatin lowered LDL cholesterol by a mean of 8.2% more than atorvastatin, 26% more than pravastatin and 12% to 18% more than simvastatin; "drug tolerability was similar across treatments"7 |
| Lehtisalo and colleagues, pharmacogenomics, British Journal of Clinical Pharmacology 20232 | Genome-wide association study and candidate gene analysis of single-dose pharmacokinetics; European Research Council and Finnish foundation funding2 | 247 healthy volunteers (159 in a prospective study, 88 from earlier studies)2 | Single oral dose of 40 mg (prospective study) or 10 to 20 mg (earlier studies)2 | Poor OATP1B1 function phenotype: area under the curve 2.1-fold higher (90% CI 1.6 to 2.8); ABCG2 c.421A/A: 2.2-fold higher (1.5 to 3.0)2 |
Deeper analysis: JUPITER (Ridker and colleagues, 2008)
Ridker and colleagues, of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, Harvard Medical School, published JUPITER in the New England Journal of Medicine in 2008.3 The trial asked whether people with elevated high-sensitivity C-reactive protein but without hyperlipidemia might benefit from a statin, and it randomised 17,802 apparently healthy men and women to rosuvastatin 20 mg daily or placebo.3 The registry entry sets entry at men 50 years or older and women 60 years or older, and lists diabetes mellitus among the exclusions.4 The trial was "stopped after a median follow-up of 1.9 years (maximum, 5.0)", and the label states that the Data Safety Monitoring Board stopped it after "meeting predefined stopping rules for efficacy".3,1 Rosuvastatin "reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%".3 The primary end point rates were 0.77 and 1.36 per 100 person-years on rosuvastatin and placebo (hazard ratio 0.56; 95% CI 0.46 to 0.69).3 Death from any cause was 1.00 and 1.25 per 100 person-years (hazard ratio 0.80; 95% CI 0.67 to 0.97).3 The label reports 252 primary events on placebo against 142 on rosuvastatin, an absolute risk reduction of 1.2%.1 The label also states that there were "no significant treatment differences" between the groups for death due to cardiovascular causes or hospitalizations for unstable angina.1 In a post hoc subgroup of 725 rosuvastatin and 680 placebo participants with hsCRP of 2 mg/L or higher and no other traditional risk factors other than age, after adjustment for high HDL-C, the label states there was "no significant treatment benefit".1 The registry posts secondary results: diabetes mellitus hazard ratio 1.27 (95% CI 1.05 to 1.53), venous thromboembolism hazard ratio 0.57 (0.35 to 0.91), bone fracture hazard ratio 1.06 (0.88 to 1.28) and non-cardiovascular death hazard ratio 0.84 (0.65 to 1.08).4 On safety, the registry lists serious adverse events in 1,205 of 8,869 participants on rosuvastatin and 1,216 of 8,864 on placebo, and 693 rosuvastatin and 715 placebo participants did not complete the study.4 A later analysis states that at trial termination "75% of participants remained on study drug".6 AstraZeneca is the registry's lead sponsor, and the registry's description reports AstraZeneca announcing the early stop on the recommendation of an Independent Data Monitoring Board and the JUPITER Steering Committee.4 The authors of the later Lancet analysis state that JUPITER "was an investigator-initiated project funded by AstraZeneca", that Dr Ridker was principal investigator and "received grant support from AstraZeneca for its conduct", and that he is a co-inventor on patents "that have been licensed to Seimens and AstraZeneca".5 The PubMed record for the 2008 paper carries no limitations statement or funding statement, so the authors' own limitations are taken from the later analyses.3 Those authors write that "all study participants had elevated levels of CRP", that the data are "limited to rosuvastatin at a single dose (20 mg daily)", and that median follow-up was 2 years "and thus long term data on benefits and risks cannot be gleaned from this study".5
Deeper analysis: the JUPITER diabetes analysis (Ridker and colleagues, Lancet 2012)
Ridker, Pradhan, MacFadyen, Libby and Glynn analysed 17,603 JUPITER participants without prior cardiovascular disease or diabetes, stratified by whether they had at least one of metabolic syndrome, impaired fasting glucose, body-mass index of 30 kg/m2 or higher, or glycated haemoglobin above 6%.5 The risk factors "were selected post hoc on the basis of literature review".5 Overall, 270 participants on rosuvastatin and 216 on placebo had physician-reported diabetes (hazard ratio 1.25; 95% CI 1.05 to 1.49), and the average time to diagnosis was 84.3 weeks against 89.7 weeks, an acceleration of 5.4 weeks.5 The paper states that "virtually all of the excess risk of diabetes associated with rosuvastatin occurred among those with baseline evidence of impaired fasting glucose".5 In the group with risk factors, the hazard ratio was 0.61 for the primary end point (0.47 to 0.79), 0.64 for venous thromboembolism (0.39 to 1.06; P=0.08) and 0.83 for total mortality (0.64 to 1.07; P=0.15), and 134 total cardiovascular events or deaths were avoided for every 54 new cases of diabetes.5 Muscle adverse event rates per 100 person-years: muscular weakness, stiffness or pain 8.72 on rosuvastatin against 8.53 on placebo in the group without risk factors and 8.20 against 7.75 in the group with them; myopathy 0.06 against 0.06 and 0.05 against 0.04; rhabdomyolysis 0.02 against 0.0 in the group without risk factors and 0.0 against 0.0 in the group with them.5 Measured fasting glucose "levels were not significantly different" between arms, while HbA1c at 24 months was 0.1 percentage point higher on rosuvastatin (P=0.001).5 The authors conclude that "the cardiovascular and mortality benefits of statin therapy exceed the diabetes hazard", and name as limitations the elevated CRP of all participants, the single dose and a median follow-up of 2 years.5 The paper reports funding from AstraZeneca and a National Heart, Lung, and Blood Institute grant, and states that the sponsor "played no role in the conduct of these analyses, in the drafting of this manuscript, or in the decision to submit these analyses for publication".5
Deeper analysis: the JUPITER fracture analysis (Peña and colleagues, JAMA Internal Medicine 2015)
Peña, Aspberg, MacFadyen, Glynn, Solomon and Ridker (Montefiore Medical Center, Karolinska Institutet and Brigham and Women's Hospital among the affiliations) examined fracture, a prespecified secondary end point of JUPITER, with fractures confirmed by radiographs, computed tomography, bone scan or other methods.6 The result was null: 431 confirmed fractures, 1.20 and 1.14 per 100 person-years on rosuvastatin and placebo (adjusted hazard ratio 1.06; 95% CI 0.88 to 1.28; P = .53), and the authors write that statin therapy "did not reduce the risk of fracture".6 The authors name limitations: "the relatively short treatment duration may not have been sufficient to achieve a beneficial effect of statins on bone", and a fixed dose.6 AstraZeneca supported JUPITER and, per the paper, "collected the trial data and monitored study sites but did not design the study protocol, conduct analyses, interpret the data" or review the manuscript; Dr Ridker is a co-inventor on patents licensed to AstraZeneca and has received investigator-initiated grants from AstraZeneca and other companies.6
Deeper analysis: STELLAR (Jones and colleagues, 2003)
Jones and colleagues, with the first author at Baylor College of Medicine, reported STELLAR in the American Journal of Cardiology in 2003.7 It was a 6-week, open-label, randomised trial of 2,431 adults with hypercholesterolemia comparing rosuvastatin with atorvastatin, simvastatin and pravastatin at several doses, with the primary objective of LDL cholesterol reduction.7 Across doses, rosuvastatin 10 to 80 mg reduced LDL cholesterol by a mean of 8.2% more than atorvastatin 10 to 80 mg, 26% more than pravastatin 10 to 40 mg and 12% to 18% more than simvastatin 10 to 80 mg.7 Secondary results: HDL cholesterol rose by +7.7% to +9.6% in the rosuvastatin groups against +2.1% to +6.8% in the other groups.7 The record states that "drug tolerability was similar across treatments" but gives no adverse event counts, discontinuations, funding statement, author ties to the sponsor or limitations.7 The trial was open-label and ran for 6 weeks, and its record reports lipid changes and LDL cholesterol goal attainment, with no cardiovascular outcomes given.7
Doses reported in studies and on labels
| Source | Population or setting | Dose and route | Length, n and comparator | What was reported |
|---|---|---|---|---|
| Crestor label, adults1 | Adults, by indication, LDL-C and cardiovascular risk | 5 to 40 mg orally once daily, any time of day, with or without food | Label range; no comparator | "The dosage range for CRESTOR is 5 to 40 mg orally once daily"1 |
| Crestor label, pediatric HeFH1 | Heterozygous familial hypercholesterolemia, aged 8 years and older | 5 to 10 mg once daily (8 to under 10 years); 5 to 20 mg once daily (10 years and older), oral | Label range | Dose range stated by age band1 |
| Crestor label, Asian patients1 | Asian patients | Initiate at 5 mg once daily, oral | Label; risks and benefits to be considered when not controlled at up to 20 mg | "due to increased rosuvastatin plasma concentrations"1 |
| Crestor label, severe renal impairment1 | CLcr under 30 mL/min/1.73 m2, not on hemodialysis | Starting dose 5 mg once daily, oral, not to exceed 10 mg once daily | Label | "There are no dosage adjustment recommendations for patients with mild and moderate renal impairment"1 |
| Crestor label, interacting drugs1 | Taken with cyclosporine; or with gemfibrozil | Cyclosporine: label ceiling of 5 mg once daily. Gemfibrozil: label states avoid concomitant use; if unavoidable, start at 5 mg once daily with a ceiling of 10 mg | Label table of modifications | Dosage modifications listed by co-administered drug1 |
| JUPITER, Ridker 20083 | Apparently healthy adults, LDL cholesterol under 130 mg/dL, hsCRP 2.0 mg/L or higher | 20 mg daily, oral | Against placebo; n = 17,802; median 1.9 years | Primary end point hazard ratio 0.56 (0.46 to 0.69)3 |
| STELLAR, Jones 20037 | Adults with hypercholesterolemia | 10, 20, 40 or 80 mg, oral | 6 weeks; n = 2,431; against atorvastatin, simvastatin, pravastatin | LDL cholesterol lowered by a mean of 8.2% more than atorvastatin across doses7 |
Sources in this part
Side effects reported
Sources in this part
The label lists the most frequent adverse reactions (rate of 2% or more) as headache, nausea, myalgia, asthenia and constipation.1 Those rates come from placebo-controlled studies with a treatment duration of up to 12 weeks, and the label tabulates separate rates for the METEOR (40 mg, mean 1.7 years) and JUPITER trials.1 The label states that "in JUPITER, there was a significantly higher frequency of diabetes mellitus reported in patients taking CRESTOR (2.8%) versus patients taking placebo (2.3%)", and that mean HbA1c was "significantly increased by 0.1%".1 The label warns that rosuvastatin "may cause myopathy" and rhabdomyolysis, with acute kidney injury and rare fatalities reported with statins.1 Listed risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, certain other drugs and higher dosage, and the label states that the risk "is greater in patients taking CRESTOR 40 mg daily compared with lower CRESTOR dosages".1 In a pooled analysis of placebo-controlled trials, serum transaminases above three times the upper limit of normal occurred in 1.1% on rosuvastatin and 0.5% on placebo, with rare postmarketing reports of fatal and non-fatal hepatic failure.1 In a 12-week pediatric study (aged 10 to 17 years with HeFH), CK above 10 times the upper limit of normal occurred in 4 of 130 (3%) on rosuvastatin and 0 of 46 on placebo.1 The label lists acute liver failure or decompensated cirrhosis as a contraindication.1
Bloodwork and markers
Sources in this part
Regulatory and anti-doping status
Sources in this part
The US label gives 2003 as the initial approval year for Crestor.1 The Lancet analysis reports that on 1 March 2012 the US Food and Drug Administration "added a warning regarding diabetes risk to the labeling of all statin agents".5 The WADA Prohibited List 2026 is valid from 1 January 2026.8 A text search of the list for "statin" returned only "myostatin" entries, and no entry for rosuvastatin or for HMG-CoA reductase inhibitors was identified.8
Storage and handling
Sources in this part
The label gives storage at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C, and "protect from moisture".1
What is not known
The sources read for rosuvastatin do not settle why the label's half-life of approximately 19 hours differs from the 10.9-hour geometric mean in healthy volunteers, and the app's figure follows the label.1,2 The app's description of 19 hours as the longest half-life of the commonly used statins was not tested: none of the sources used compares half-lives across statins. The label states that the effect of the SLCO1B1 variant on efficacy or safety "has not been clearly established", although the Lehtisalo study reports higher exposure with reduced OATP1B1 function.1,2 JUPITER followed participants for a median of 1.9 years, and its authors write that long-term data on benefits and risks "cannot be gleaned from this study".3,5 The JUPITER results come from apparently healthy people with elevated hsCRP and LDL cholesterol under 130 mg/dL, and the label reports no significant treatment benefit in a post hoc subgroup with hsCRP of 2 mg/L or higher and no other traditional risk factors other than age, after adjustment for high HDL-C.3,1
Frequently asked questions
What is the half-life of rosuvastatin?
What is the bioavailability of rosuvastatin?
The label gives the absolute bioavailability of rosuvastatin as approximately 20%, matching the app's 20%.1
How long does rosuvastatin take to reach its peak level?
Is rosuvastatin banned by WADA?
Is rosuvastatin metabolised by CYP3A4?
Does SLCO1B1 genotype change rosuvastatin levels?
In 247 healthy volunteers, the poor OATP1B1 function phenotype associated with a 2.1-fold higher area under the curve (90% confidence interval 1.6 to 2.8).2
What did the JUPITER trial find for rosuvastatin?
In JUPITER (17,802 people, rosuvastatin 20 mg daily or placebo, median follow-up 1.9 years) the primary end point hazard ratio was 0.56 (95% CI 0.46 to 0.69).3 The same trial reported a higher incidence of physician-reported diabetes on rosuvastatin, 270 reports against 216 on placebo, and AstraZeneca funded it.3,5
Guides, tools and comparisons
References
- AstraZeneca. Crestor (rosuvastatin) tablets, film coated, for oral use. US prescribing information, DailyMed record version 19, 30 September 2026. DailyMed label
- Lehtisalo M, et al. A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics. Br J Clin Pharmacol 2023. PMID 35942816
- Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008. PMID 18997196
- AstraZeneca. JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events. ClinicalTrials.gov NCT00239681. NCT00239681
- Ridker PM, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012. PMID 22883507
- Peña JM, et al. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. JAMA Intern Med 2015. PMID 25437881
- Jones PH, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003. PMID 12860216
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list